STRENGTH
Long-Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia (STRENGTH)
- Stadium
- klaar
- Middel
- epanova
- Populatie
- ASCVD
- Fase
- III
- First Patient In
- 15 februari 2015
- Last Patient In
- 14 april 2017
- Last Patient Last Visit
- 31 augustus 2020
National Lead
dr. mr. A.J.M. Oude Ophuis
Cardioloog
Studiedirecteur
